Get The Daily Rip

Stocktwits Top 25 – Week 11 πŸ“ˆ

Welcome to the Stocktwits Top 25 Newsletter for Week 11 of 2023!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time.Β 

Here are the Stocktwits Top 25 Lists for Week 11:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Standard and Poor's 500

ST Top 25 S&P 500

The S&P 500 Top 25 list (+4.02%) outperformed the S&P 500 index (+1.43%).

There were four major changes to the list this week.

Joining: Arista Networks (+11.47%), FedEx (+9.50%), Applied Materials (+7.18%), and Fortinet (+4.19%).

Leaving: United Airlines (-15.56%), Steel Dynamics (-13.67%), Booking Holdings (-1.60%), and WW Grainger (-2.12%).

Check out how the momentum meter has performed vs. the S&P 500 index this year:


The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+5.76%) underperformed the Nasdaq 100 index (+5.83%).

There were four major changes to the list this week.

Joining:Β Amazon(+9.06%), Synopsys (+4.87%), Microsoft (+12.41%), and ASML Holding (+5.40%).

Leaving:Β Microchip Technology(-1.05%), Lucid Group (-2.29%), Copart (+1.93%), and IDEXX Laboratories (+3.63%).


The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+25.21%) outperformed the Russell 2000 index (-2.64%).

There were ten major changes to the list this week.

Joining: Riot Platforms (+52.83%), Marathon Digital Holdings (+53.28%), Provention Bio (+258.06%), Tyra Biosciences (+26.57%), Ironnet Inc (+35.29%), Redfin Inc (+22.62%), MicroStrategy (+39.40%), Fastly (+15.25%), Berkshire Grey (+15.46%), and Home Point Capital (+34.21%).

Leaving: Boxed Inc (-76.74%), Manitowoc Company (-9.01%), Blue Bird Corp (-6.16%), Diebold Nixdorf (-65.07%), Skywater Technology (-16.45%), BridgeBio Pharma (-3.63%), Hyster-Yale Materials Handling (-7.04%), Universal Insurance Holdings (-5.02%), Ocular Therapeutix (+1.85%), and Indie Semiconductor (+2.48%).



The Top 25 lists’ Top Dawg was Provention Bio, which rallied 258.06%. πŸ“ˆ

The small-cap clinical-stage biopharmaceutical company jumped on the news that Sanofi will buy the company in a $2.9 billion all-cash deal. Sanofi will use the acquisition to bolster its work on a U.S.-approved type 1 diabetes therapy and strengthen its drug pipeline following development setbacks. πŸ’‰

The two companies previously had a co-promotion agreement, but now the French drug maker will fully own the Tzield drug. The acquisition is expected to be completed in the second quarter of 2023. 🀝

$PRVB is up 126.96% YTD.

See Y’all Next Week πŸ€™